Literature DB >> 12511601

Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions.

Raj Kumar1, E Brad Thompson.   

Abstract

The N-terminal domains (NTDs) of many members of the nuclear hormone receptor (NHR) family contain potent transcription-activating functions (AFs). Knowledge of the mechanisms of action of the NTD AFs has lagged, compared with that concerning other important domains of the NHRs. In part, this is because the NTD AFs appear to be unfolded when expressed as recombinant proteins. Recent studies have begun to shed light on the structure and function of the NTD AFs. Recombinant NTD AFs can be made to fold by application of certain osmolytes or when expressed in conjunction with a DNA-binding domain by binding that DNA-binding domain to a DNA response element. The sequence of the DNA binding site may affect the functional state of the AFs domain. If properly folded, NTD AFs can bind certain cofactors and primary transcription factors. Through these, and/or by direct interactions, the NTD AFs may interact with the AF2 domain in the ligand binding, carboxy-terminal portion of the NHRs. We propose models for the folding of the NTD AFs and their protein-protein interactions.

Mesh:

Substances:

Year:  2003        PMID: 12511601     DOI: 10.1210/me.2002-0258

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  56 in total

Review 1.  Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation.

Authors:  Raj Kumar; Iain J McEwan
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Regulation of the structurally dynamic N-terminal domain of progesterone receptor by protein-induced folding.

Authors:  Raj Kumar; Carmen M Moure; Shagufta H Khan; Celetta Callaway; Sandra L Grimm; Devrishi Goswami; Patrick R Griffin; Dean P Edwards
Journal:  J Biol Chem       Date:  2013-08-30       Impact factor: 5.157

Review 3.  Estrogen receptor-α and estrogen receptor-β in the uterine vascular endothelium during pregnancy: functional implications for regulating uterine blood flow.

Authors:  Mayra B Pastore; Sheikh O Jobe; Jayanth Ramadoss; Ronald R Magness
Journal:  Semin Reprod Med       Date:  2012-01-23       Impact factor: 1.303

Review 4.  Chromatin dynamics and the evolution of alternate promoter states.

Authors:  Gordon L Hager; Cem Elbi; Thomas A Johnson; Ty Voss; Akhilesh K Nagaich; R Louis Schiltz; Yi Qiu; Sam John
Journal:  Chromosome Res       Date:  2006       Impact factor: 5.239

5.  Thermodynamic analysis of progesterone receptor-promoter interactions reveals a molecular model for isoform-specific function.

Authors:  Keith D Connaghan-Jones; Aaron F Heneghan; Michael T Miura; David L Bain
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-02       Impact factor: 11.205

6.  Cooperative DNA binding by the B-isoform of human progesterone receptor: thermodynamic analysis reveals strongly favorable and unfavorable contributions to assembly.

Authors:  Aaron F Heneghan; Keith D Connaghan-Jones; Michael T Miura; David L Bain
Journal:  Biochemistry       Date:  2006-03-14       Impact factor: 3.162

Review 7.  Ecdysteroid hormone action.

Authors:  Klaus-Dieter Spindler; C Hönl; Ch Tremmel; S Braun; H Ruff; M Spindler-Barth
Journal:  Cell Mol Life Sci       Date:  2009-12       Impact factor: 9.261

8.  Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Koen Dechering; Tsang Wai Lam; Angus R Brown; Niall M Hamilton; Olaf Nimz; Rolien Bosch; Ross McGuire; Arthur Oubrie; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2011-08-17       Impact factor: 5.157

Review 9.  Structural dynamics, intrinsic disorder, and allostery in nuclear receptors as transcription factors.

Authors:  Vincent J Hilser; E Brad Thompson
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

10.  Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.

Authors:  Suzanne E Wardell; Ramesh Narayanan; Nancy L Weigel; Dean P Edwards
Journal:  Mol Endocrinol       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.